1 BTC
=
- USD
MiNK Therapeutics, Inc. Common Stock
As of May 30, 2026 at 24:05 UTC
Chart
About MiNK Therapeutics, Inc. Common Stock
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.
Market Statistics
Trading Metrics
How to Buy INKT
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy INKT
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesMiNK Therapeutics announced Phase II trial results for agenT-797 combined with botensilimab and balstilimab in PD-1 refractory gastroesophageal cancer. The study achieved a 77% disease control rate with long-term survival beyond 20 months in a subset of patients. An induction treatment strategy showed significant improvements in progression-free survival (6.9 vs. 3.5 months) and overall survival (9.5 vs. 5.2 months), though the trial did not meet its primary endpoint of objective response rate.
MiNK Therapeutics announced that Phase II trial data from Memorial Sloan Kettering Cancer Center evaluating agenT-797 (an allogeneic iNKT cell therapy) combined with botensilimab and balstilimab in PD-1 refractory gastroesophageal cancer will be presented at AACR 2026. The study represents one of the first clinical evaluations of iNKT cell therapy combined with dual checkpoint modulation in this indication, addressing an area of high unmet medical need.
MiNK Therapeutics presented translational data at Keystone Symposia demonstrating significant depletion of iNKT cells in lung tissue from advanced IPF patients, supporting the mechanistic rationale for iNKT cell replenishment as a potential therapeutic approach. The findings expand MiNK's iNKT platform into chronic fibrotic lung disease, addressing a large unmet medical need affecting approximately 100,000 U.S. patients with limited treatment options.
MiNK Therapeutics presented clinical results showing promising immune cell therapy agenT-797 demonstrated durable responses and immune reactivation in patients with checkpoint-resistant solid tumors, with some patients experiencing complete remission lasting over two years.
MiNK Therapeutics reported a Q2 2025 net loss of $1.06 per share, with no revenue but promising clinical progress in iNKT cell therapies for cancer and immune diseases. The company raised $13 million in equity and continues advancing its lead product agenT-797 in clinical trials.